Market Overview

ChemoCentryx Says Glaxo's Top-Line Results from SHIELD-1 Phase III Study of Vercirnon Did Not Meet Primary Endpoint

Related GSK
EXCLUSIVE: FBB's Mike Bailey On Pfizer-Allergan Deal, Taxes, Rate Hike And Biotech Picks
Idera to Collaborate With GSK to Identify 3rd Generation Antisense Molecules for Treatment of Renal Disease
Skin Disease Drug Costs Jump (Investor's Business Daily)
Related CCXI
Wednesday's After-Hours Movers: 10 Stocks To Watch
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 3

ChemoCentryx, Inc. (Nasdaq: CCXI) reports that GlaxoSmithKline (NYSE: GSK) announced today that the first of four Phase III studies, the SHIELD-1 study, investigating vercirnon, an inhibitor of the chemokine receptor known as CCR9, in patients with moderate-to-severe Crohn's disease did not achieve the primary endpoint of improvement in clinical response and the key secondary endpoint of clinical remission. The rates of serious adverse events and withdrawals due to adverse events were similar among all treatment groups including the placebo group, with a trend in dose-dependent increases in overall adverse event rates. GSK has indicated that it intends to continue to explore the safety and efficacy results to inform decisions about the clinical development program for vercirnon. New recruitment and dosing in the ongoing clinical program has been suspended pending further review of the SHIELD-1 results.

Posted-In: News FDA


Related Articles (GSK + CCXI)

View Comments and Join the Discussion!

Get Benzinga's Newsletters